Every major neurotoxin and filler brand - Botox, Dysport, Xeomin, Jeuveau, Daxxify, Juvederm, Restylane, Belotero, Radiesse, Sculptra, Bellafill, Revanesse - is a prescription drug or medical device with a specific FDA approval for specific indications. When a med spa markets these products by brand name, the marketing becomes subject to the FDA’s prescription drug and device advertising rules - which are significantly stricter than the general marketing rules most clinics think of as their compliance surface.
This post walks through how the rules actually apply to typical med spa marketing, the specific phrasings that produce violations, and what compliant brand-mention practice looks like. This is one of the highest-density compliance topics in med spa marketing because virtually every clinic does some version of this wrong.
The regulatory framework, simplified
The core rules at play:
- Prescription drug advertising (21 CFR 202.1).Direct-to-consumer advertising of prescription drugs requires specific format - fair balance between benefits and risks, risk information presented with equal prominence, disclosure of approved indications, and other structural requirements.
- Medical device advertising (Section 502 FD&C Act). Devices are subject to misbranding rules if their labeling (including advertising) is false or misleading or omits required information.
- Off-label promotion prohibition. Manufacturers cannot promote products for uses outside their FDA-approved labeling. Clinics adopting manufacturer-style off-label promotion share in the exposure.
- Trademark considerations. Manufacturers control how their trademarks are used. Brand-name misuse can generate cease-and-desist letters from the manufacturer independent of FDA action.
Who these rules apply to
The core confusion among med spas is thinking the brand-name advertising rules apply only to manufacturers. They apply to anyone whose advertising uses the brand name to promote the product - including clinics.
The FDA has specifically taken action against clinics marketing prescription drugs in ways that promote the drug itself (rather than the clinic’s services generally). The distinction often turns on how the marketing is framed: promoting “the clinic offers neuromodulator treatments” lands differently than promoting “get Botox for 20% off this weekend.”
The specific problem patterns
Pattern 1: Brand-name specials and discounts
“Botox Tuesday! $12 per unit this week only.”
“Neurotoxin Tuesday - $12 per unit on neuromodulator treatments this week.”
Why: Using brand names in discount marketing crosses into drug-advertising territory. The compliant framing uses generic treatment names while preserving the promotional message.
Pattern 2: Provider-linked brand marketing
“Botox by Nurse Smith - book directly!”
“Neuromodulator injections by Nurse Smith (NP), performed under the supervision of our medical director.”
Why: Provider-linked brand marketing combines two compliance issues: brand advertising and supervision misrepresentation. The compliant version uses generic treatment language plus explicit supervision disclosure.
Pattern 3: Off-label indication promotion
“Botox for non-surgical chin slimming and nose reshaping.”
“We offer neuromodulator and filler treatments for a range of concerns - candidacy and specific applications discussed at consultation. (Note: off-label use should be clinically appropriate and documented in patient records.)”
Why: Marketing specific off-label indications for an FDA-approved drug is explicit off-label promotion, which the FDA has pursued against clinics directly.
Pattern 4: Before/after with brand attribution
“Maria's lips - 2 syringes of Juvederm. Book your Juvederm today!”
“Maria, 6 weeks post-treatment. Individual results vary. Filler treatments with products selected based on candidacy - discussed at consultation.”
Why: Before/after attribution to specific brand products creates an implicit brand testimonial, which the manufacturer typically controls and which the FTC reads under Endorsement Guides.
Pattern 5: Brand comparative advertising
“Why Dysport beats Botox at our clinic.”
“Why we may recommend one neuromodulator over another based on your specific treatment goals - learn more at consultation.”
Why: Direct brand comparisons in advertising implicate both FDA comparative-advertising rules and manufacturer trademark concerns. Non-branded discussion of why product choice matters preserves the message without the exposure.
Pattern 6: “FDA-approved” brand marketing
“FDA-approved Botox for deeper wrinkles and fuller lips.”
“Botox Cosmetic is FDA-approved for the temporary improvement in the appearance of glabellar lines, lateral canthal lines, and forehead lines in adults. Our providers assess candidacy for each individual.”
Why: FDA-approved applied broadly misrepresents the specific labeled indications. The compliant version discloses the actual labeling, which is informative and defensible.
Compliant framing - the practical patterns
There are several framings that preserve marketing message while keeping the brand-advertising exposure contained.
Framing 1: Practice-promotion rather than product-promotion
Market your practice - “our aesthetic injectables team,” “neuromodulator treatments at our clinic” - rather than specific branded products. You can still mention the brands clients ask about or the specific products you stock when it’s clinically relevant. But leading with the practice rather than the brand shifts the marketing category.
Framing 2: Clinical-appropriateness language
“We select the appropriate product for each patient based on treatment goals and anatomy” is stronger marketing than “we do Botox and Dysport” because it positions the provider’s judgment rather than the product list. It also keeps brand-specific claims out of the public marketing.
Framing 3: Disclosure-paired brand mentions when necessary
When brand names are necessary (consent forms, educational content, specific product information pages), pair them with proper disclosure: specific approved indications, major side effects, and clinical appropriateness determination. This is how manufacturers structure their own DTC advertising, and the same template works for clinic-level brand mentions.
Framing 4: Consultation-forward positioning
Marketing that leads to consultation (rather than leads to a specific product purchase) inherently avoids much of the brand-advertising risk. “Book a consultation to discuss your goals and determine the right treatment plan” is both conversion-optimized and compliance-optimized.
Manufacturer cease-and-desist letters
Beyond FDA exposure, brand-name misuse frequently triggers cease-and-desist letters from the manufacturer directly. Allergan, Galderma, Merz, and other manufacturers have internal compliance teams that monitor how their products are being marketed - and they send cease-and-desist letters when clinic marketing crosses into trademark territory or creates false impressions about approved indications.
Most of these letters are resolved quickly when the clinic corrects the marketing. But ignoring them can escalate to trademark litigation, product-allocation issues (some manufacturers control who gets product access based on compliance posture), and in rare cases, parallel FDA referral.
Social media specifics
Instagram, TikTok, and YouTube are the primary surfaces where brand-advertising issues surface in med spa marketing. A few specific considerations:
Captions
Captions using brand names in promotional contexts (“Botox special,” “Juvederm day”) carry the same exposure as website marketing. Generic treatment-category captions with brand names in clinical-appropriateness contexts when necessary hold up better.
Stories and highlights
Story highlights often stick around as compliance records long after individual stories expire. Audit highlights the same way you audit permanent content.
Reels and videos
On-screen text, voiceover, and caption all carry claim content. Product placement showing branded packaging counts as implicit brand marketing.
Paid ads
Paid advertising on Meta, TikTok, and Google adds platform policy on top of FDA and FTC rules. Platform healthcare-ad policies have their own brand-name restrictions that often overlap with FDA rules but are not identical.
Frequently asked questions
Can I say the word Botox at all?
Yes - in appropriate contexts. Consent forms, educational content, in-consultation discussion, FAQs about specific products. The issue is using brand names in promotional contexts (ads, specials, before/after attribution, social media captions designed to drive conversion) rather than in informational contexts.
What about product I stock vs. product I don’t?
Listing what you stock is fine in an informational context. Promoting specific stocked brands as the reason to book is where marketing crosses into brand-advertising territory. Most clinics find they can preserve marketing force by shifting to practice-promotion framing while still informing patients about specific products during consultation.
Does this apply to fillers the same way as neurotoxins?
Yes, with some differences. Fillers are technically medical devices rather than drugs, but the marketing framework is similar - brand-name specials, off-label promotion, and comparative claims carry similar exposure. Some fillers have specific approved indications that are worth knowing (e.g., lip augmentation, nasolabial folds).
What about aesthetic laser brands?
Similar framework. Marketing by brand name (“Fraxel,” “CoolSculpting,” “Morpheus8,” “Ultherapy”) for specific indications implicates both FDA-cleared vs FDA-approved confusion and manufacturer trademark concerns. The general compliant framework applies.
What about manufacturer-approved co-op marketing?
Manufacturers sometimes provide co-op marketing materials or approved templates. Using these as-provided is typically safe because the manufacturer has vetted the language. Modifying them - adding your own claims, discount language, or attribution - removes the vetting and puts you back in the standard compliance landscape.
How do I train my front desk to handle brand-name questions?
Script: “We offer neuromodulator and filler treatments. Your provider will discuss which specific products are appropriate for your goals during your consultation. We carry [list] and can explain the differences at your visit.” This answers the question (yes, we offer these treatments), names products when clinically-relevant (you carry them), and positions selection as the provider’s clinical judgment.